Pioneering Novel Antibiotics for Lung Infection
Vantacs is a research group in Queen’s University Belfast working on the development of novel antibiotics for the treatment of lung infection
Our Mission
Vantacs is a dedicated research group based at Queen’s University Belfast, committed to advancing the treatment of lung infections through innovative antibiotic development. Our team comprises leading scientists, researchers, and medical experts who are passionate about making a tangible difference in the lives of patients suffering from chronic lung diseases.
Our mission is to address the critical issue of chronic bacterial infections in the lungs, particularly for patients with conditions such as chronic obstructive pulmonary disease (COPD). We strive to develop novel, host-directed therapies that not only target harmful bacteria but also empower the body’s immune system to effectively clear infections, thereby reducing the prevalence and impact of antimicrobial resistance.
The Problem
Chronic bacterial infections in the lungs of COPD patients pose a significant health challenge, leading to inflammation and lung damage. Traditional antibiotics often fall short in effectively managing these infections and contribute to antimicrobial resistance.
Our Solution
Our aim will be to deliver the drug directly to the lung and thereby act on bacteria in the lung which cause issues with inflammation and lung damage. In addition, as this is a non-conventional antibiotic – it does not act directly on the bacteria but acts on the immune system to more effectively clear the bacteria – it may help with the issue of antimicrobial resistance
Effective Bacterial Eradication
We will work with clinicians and patients to develop an antibiotic that more effectively reduces bacteria in the lungs of patients with lung diseases such as COPD
Enhanced Immune Response
We have developed an effective host-directed drug that may be able to reduce the levels of harmful bacteria during lung infection for example, in patients with COPD.
Reduction in Antimicrobial Resistance
Our project aims to address the issue of chronic bacterial infection in the lungs of patients with lung disease
Share Your Insights
We greatly appreciate your time and feedback. By completing this survey, you are contributing valuable insights that will help us refine our innovative aerosolized antibacterial therapy for COPD. Your input is crucial in ensuring that our treatment meets the needs and expectations of patients, caregivers, and healthcare professionals.
Our Vision
We envision a future where chronic lung infections are effectively managed, and patients with lung diseases can enjoy improved health and quality of life. Through relentless innovation, rigorous research, and strategic partnerships, Vantacs aims to be at the forefront of antibiotic development, setting new standards in the treatment of lung infections.
Join us on our journey to transform the landscape of respiratory medicine and bring hope to millions of patients worldwide.
Meet The Team
Prof Cliff Taggart
Queen’s University Belfast
Dr Aoife Rodgers
Lecturer in Respiratory Immunology, Queen’s University Belfast
Prof John Dalton
Professor or Molecular Parasitology, University of Galway